Health Catalyst Inc (HCAT) Stock Falls on Q4 2025 Earnings

Health Catalyst Inc (HCAT) reported fourth-quarter 2025 results with total revenue of $74.7 million, down 6.19% year-over-year.

Revenue: $74.7 million (down 6.19% YoY)

Gross profit: $39.4 million (up 13.53% YoY)

Operating loss: $86.1 million (improved 391.89% YoY)

Net loss attributable to common shareholders: $91.0 million (improved 340.31% YoY)

Diluted earnings per share: -$1.28 (improved 287.88% YoY)

Results missed consensus estimates: revenue versus an expected $75.5 million, and diluted EPS versus an expected $0.09.

Cash from operating activities: $9.9 million (down 381.03% YoY)

Purchases of property, plant and equipment: $0.3 million (down 33.9% YoY)

Cash and cash equivalents: $50.8 million (down 79.65% YoY)

Cost of sales: $35.3 million (down 21.42% YoY)

Total liabilities: $256.9 million (down 47.97% YoY)

Shares of Health Catalyst Inc (HCAT) fell 19.42% since market close. Despite stronger gross profit, the company remains unprofitable and experienced steep declines in cash balances year-over-year.

Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.

Health Catalyst Inc Insider Trading Activity

Health Catalyst Inc insiders have traded $HCAT stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $HCAT stock by insiders over the last 6 months:

JULIE LARSON-GREEN sold 47,997 shares for an estimated $128,348
BENJAMIN LANDRY (General Counsel) sold 27,425 shares for an estimated $72,327

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

Health Catalyst Inc Hedge Fund Activity

We have seen 58 institutional investors add shares of Health Catalyst Inc stock to their portfolio, and 105 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

PORTOLAN CAPITAL MANAGEMENT, LLC removed 1,980,409 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $5,644,165
PRIMECAP MANAGEMENT CO/CA/ removed 1,028,649 shares (-75.1%) from their portfolio in Q4 2025, for an estimated $2,458,471
RA CAPITAL MANAGEMENT, L.P. added 793,749 shares (+inf%) to their portfolio in Q4 2025, for an estimated $1,897,060
FIRST LIGHT ASSET MANAGEMENT, LLC removed 525,279 shares (-3.9%) from their portfolio in Q4 2025, for an estimated $1,255,416
MILLENNIUM MANAGEMENT LLC removed 504,693 shares (-31.8%) from their portfolio in Q4 2025, for an estimated $1,206,216
SCHRODER INVESTMENT MANAGEMENT GROUP removed 468,692 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $1,335,772
HIGHMARK WEALTH MANAGEMENT LLC added 431,200 shares (+139.0%) to their portfolio in Q4 2025, for an estimated $1,030,568

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Health Catalyst Inc Analyst Ratings

Wall Street analysts have issued reports on $HCAT in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Keybanc issued a "Overweight" rating on 10/08/2025

To track analyst ratings and price targets for Health Catalyst Inc, check out Quiver Quantitative's $HCAT forecast page.

Health Catalyst Inc Price Targets

Multiple analysts have issued price targets for $HCAT recently. We have seen 6 analysts offer price targets for $HCAT in the last 6 months, with a median target of $3.875.

Here are some recent targets:

Daniel Grosslight from Citigroup set a target price of $2.75 on 01/09/2026
David Grossman from Stifel set a target price of $3.75 on 11/11/2025
Stan Berenshteyn from Wells Fargo set a target price of $5.0 on 11/11/2025
Elizabeth Anderson from Evercore ISI Group set a target price of $3.0 on 10/08/2025
Scott Schoenhaus from Keybanc set a target price of $4.0 on 10/08/2025
Sarah James from Cantor Fitzgerald set a target price of $4.0 on 10/07/2025